Pharma's Market

SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- 5 Stocks That Benefit from Health Care Legislation: Analysts

MORE HEADLINES

» Markets | Economy | Companies

- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior

PHARMA'S MARKET VIDEO

» More

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

Cholesterol Drug Battle: Merck vs. Abbott Labs

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, shares her reaction.

Cholesterol Drug Battle 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Novo Nordisk CEO on Diabetes Epidemic

13 Nov 2009

Diabetes is a global epidemic that presents an estimated $25 billion drug and device market and some predict that number could double over the next several years. Lars Sorensen, CEO of Novo Nordisk, the world's largest diabetes care company, talks to CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Merck: Live Long And Prosper

Published: Wednesday, 4 Nov 2009 | 1:45 PM ET

Text Size

By: Mike Huckman
CNBC Correspondent

I am not a Trekkie. In fact, sci-fi and fantasy are two of of my least favorite genres. But the Vulcan salutation was one of the first things I thought of when I went to the facelifted Merck Web site this morning to link to and print the press release about the new Merck. (The Schering-Plough deal closed late yesterday.)

What reminded me of Star Trek was the new corporate tagline, "Be well."

It used to be "Patients come first."

I don't know what was wrong with that one besides maybe being a bit tired. I'm assuming patients still do come first, but they've apparently taken at least a branding back seat now to "Be well."

Separately, I wonder if there's gonna be any kind of legal conflict with MSNBC's Dr. Nancy Snyderman's Web site called, yep, Be Well.

Merck advertisement
Source: USA Today
Merck advertisement
And, of course, what would day one of a mega-merger be without a full-page newspaper ad?

I don't get why companies feel obligated to spend however much money on such campaigns (Pfizer is still running a big ad in this week's Barron's) especially when one of their first actions upon closure of a deal is to hand out pink slips.

I can't imagine that those who are being let go appreciate staring at expensive, happy ads all over the place touting how great the new company will be without them. But what do I know?

Pfizer [PFE Loading... () ] put babies in its Pfizer-Wyeth ads.

Merck's [MRK Loading... () ] going with a kid and the bizarre line, "Catch a case of the giggles."

Huh?

The updated website homepage is chockfull of eye candy and other new slogans featured in a pretty slick slideshow.

Among them: "More paths to pursue our passion." "Providing free medicines to more Americans." "A shining example of environmental commitment." But I also found a glaring grammatical error on the one that features an African village photo: "Helping to protecting (sic) the sight of future generations." Oops! How did that happen? By the time you check it out, I'm betting it might already be corrected.

Merck's website used to be very bland, boring and stodgy. Behemoth pharmaceutical companies are trying to create the image of being more like younger, hipper biotech. The challenge for Merck and its competitors is to actually become more like biotech.

Update: It took a couple of hours since Pharma's Market brought it to their attention, but they've fixed the Merck homepage error. It now says, "Helping to protect the sight of future generations." My bill is in the mail (kidding).

Questions? Comments? and follow me on Twitter at mhuckman